In vivo, we demonstrated that cholesterol removal by hydroxypropyl-β-cyclodextrin protects from the progression of renal disease in several mouse models, including mouse models for DKD (ob/ob mice) [51], FSGS (NFATc1nuc) [50] and renal disease associated with Alport Syndrome (Col4a3) [52], though the effect of β-cyclodextrin on cellular cholesterol is ABCA1-independent [53]. The gene discussed is ABCA1; the disease is kidney disorder.